Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 80

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 80
---
 or the United
States, and these foreign laws may also be subject to change. Publication of discoveries in the scientific literature often lag behind
the actual discoveries, and patent applications typically are not published until 18 months after filing or, in some cases, not at all.
Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions.

| 40 |

Previously, in the United
States, assuming the other requirements for patentability are met, the first to make the claimed invention was entitled to the patent.
Outside the United States, the first to file a patent application is entitled to the patent. In March 2013, the United States transitioned
to a “first to file” system in which the first inventor to file a patent application will be entitled to the patent. Under
either the previous or current system, third parties will be allowed to submit prior art prior to the issuance of a patent by the United
States Patent and Trademark Office, and may become involved in opposition, derivation, reexamination, inter-partes review or interference
proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position with
respect to third parties.

Our commercial success depends, in part, upon our not infringing intellectual property rights owned by others.

Although we believe that we
have proprietary platforms for our technologies and product candidates, we cannot determine with certainty whether any existing third
party patents or the issuance of any third party patents in the future would require us to alter our technology, obtain licenses or cease
certain activities. We may become subject to claims by third parties that our technology infringes their intellectual property rights,
in which case we will have no option other than to defend the allegation, which may be possible to resolve through negotiation or which
might result in court proceedings. An adverse outcome in any of these circumstances is that we might be subject to significant liabilities,
be required to cease using a technology or to pay license fees (both prospectively and retrospectively); and may be subject to the payment
of significant damages. We could incur substantial costs in any litigation or other proceedings relating to patent rights, even if it
is resolved in our favor. If the proceedings occur in the United States, it is likely